| Assay ID | Title | Year | Journal | Article |
|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID55899 | Bmax2 from dihydropyridine receptor binding assay in guinea pig myocardial membranes | 1988 | Journal of medicinal chemistry, May, Volume: 31, Issue:5
| Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers. |
| AID76978 | Inhibition of muscarinic receptor mediated [Ca2+] dependent contraction of guinea pig ileal longitudinal smooth muscle | 1982 | Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
| Crystal structures and pharmacological activity of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-(unsubstituted, 2-methyl-, 4-methyl-, 3-nitro-, 4-nitro-, and 2,4-dinitrophenyl)-1,4-dihydropyridine. |
| AID228679 | Solvation energy | 1999 | Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
| Stereoselective characterization of the 1,4-dihydropyridine binding site at L-type calcium channels in the resting state and the opened/inactivated state. |
| AID77341 | Calcium channel antagonistic activity relative to 2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester(=100) | 1982 | Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
| Crystal structures and pharmacological activity of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-(unsubstituted, 2-methyl-, 4-methyl-, 3-nitro-, 4-nitro-, and 2,4-dinitrophenyl)-1,4-dihydropyridine. |
| AID55897 | Bmax1 from dihydropyridine receptor binding assay in guinea pig myocardial membranes | 1988 | Journal of medicinal chemistry, May, Volume: 31, Issue:5
| Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers. |
| AID76358 | Compound was tested for its antagonist activity against calcium channel | 1988 | Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
| 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. |
| AID95740 | Evaluated for the free energies of binding (delta G) (in the resting state (rs) of voltage-gated L-type [Ca2+] channel (VGCCs)) | 1999 | Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
| Stereoselective characterization of the 1,4-dihydropyridine binding site at L-type calcium channels in the resting state and the opened/inactivated state. |
| AID45604 | Negative log antagonist concentration causing 50% displacement of [3H]nifedipine from guinea pig ileal smooth muscle membrane. | 1987 | Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
| Synthesis and calcium channel antagonist activity of dialkyl 4- (dihydropyridinyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylates. |
| AID58621 | In vivo antihypertensive activity against anaesthetized dogs after intravenous administration of specified threshold dose | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5
| Synthesis, pharmacological effects, and conformation of 4,4-disubstituted 1,4-dihydropyridines. |
| AID76357 | Effective concentration required to produce mechanical response determined in muscle strips of guinea pig | 1988 | Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
| 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. |
| AID195183 | Vasodilator activity was measured on rat aorta in the presence of ODQ. | 1998 | Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
| New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. |
| AID167659 | Compound was tested for ability to relax potassium-contracted rabbit aorta smooth muscle | 1988 | Journal of medicinal chemistry, May, Volume: 31, Issue:5
| Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers. |
| AID195182 | Vasodilator activity was measured on rat aorta in the presence of guanylate cyclase methylene blue(MB). | 1998 | Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
| New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. |
| AID45618 | Dissociation constant for inhibition of [3H]nitrendipine binding to guinea pig myocardial membranes | 1988 | Journal of medicinal chemistry, May, Volume: 31, Issue:5
| Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers. |
| AID76980 | Inhibition of muscarinic receptor mediated [Ca2+] dependent contraction of guinea pig ileal longitudinal smooth muscle. | 1987 | Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
| Synthesis and calcium channel antagonist activity of dialkyl 4- (dihydropyridinyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylates. |
| AID47566 | Binding affinity for L-type [Ca2+] channels was measured through displacement of [3H]nitrendipine on rat cortex homogenates. | 1998 | Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
| New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. |
| AID167811 | Evaluated in vitro for the inhibition of KCl-induced contraction of isolated rabbit aorta rings. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5
| Synthesis, pharmacological effects, and conformation of 4,4-disubstituted 1,4-dihydropyridines. |
| AID45619 | Dissociation constant for inhibition of [3H]nitrendipine binding to guinea pig myocardial membranes | 1988 | Journal of medicinal chemistry, May, Volume: 31, Issue:5
| Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers. |
| AID47565 | Inhibitory concentration for L-type [Ca2+] channels was measured through displacement of [3H]nitrendipine on rat cortex homogenates. | 1998 | Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
| New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |